Compare CMI & TAK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CMI | TAK |
|---|---|---|
| Founded | 1919 | 1781 |
| Country | United States | Japan |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 71.1B | 57.6B |
| IPO Year | 1994 | 2007 |
| Metric | CMI | TAK |
|---|---|---|
| Price | $533.12 | $18.13 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 23 | 3 |
| Target Price | ★ $741.26 | $22.00 |
| AVG Volume (30 Days) | 990.1K | ★ 2.1M |
| Earning Date | 11-05-2026 | 10-29-2026 |
| Dividend Yield | 1.68% | ★ 2.76% |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 11.44 | N/A |
| Revenue | ★ $33,670,000,000.00 | N/A |
| Revenue This Year | $11.88 | $4.39 |
| Revenue Next Year | $9.06 | $1.93 |
| P/E Ratio | $45.91 | ★ $41.25 |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $400.72 | $12.99 |
| 52 Week High | $737.76 | $19.10 |
| Indicator | CMI | TAK |
|---|---|---|
| Relative Strength Index (RSI) | 43.08 | 46.05 |
| Support Level | $527.76 | $17.95 |
| Resistance Level | $611.51 | $18.51 |
| Average True Range (ATR) | 12.88 | 0.21 |
| MACD | 3.54 | -0.14 |
| Stochastic Oscillator | 71.33 | 27.41 |
Cummins is a leading manufacturer of diesel and other engines used in heavy- and medium-duty commercial trucks, off-highway equipment, and locomotives, in addition to prime power and standby generators. The company also sells powertrain components, which include filtration products, transmissions, turbochargers, aftertreatment systems, and fuel systems. Sales are approximately 60% US and Canada and 40% rest of the world. Much of Cummins' foreign sales (China, India, and so forth) are through joint ventures. The company operates 650 distributors and over 19,000 dealer locations across 190 countries. Cummins' business model is unique as it competes with many of its heavy-duty truck manufacturer customers, which also make their own engines.
Takeda Pharmaceutical is Japan's largest pharmaceutical company, with revenue of JPY 4.5 trillion in fiscal 2025. The company's five core therapeutic areas are oncology, gastroenterology, neuroscience, rare diseases, and plasma-derived therapies, which account for more than 80% of revenue. Its geographic footprint is well diversified, with about 50% from the US, 10% from Japan, 25% from Europe, and 15% from Canada.